Biomarker‐based long‐term safety and efficacy of PD ‐1/ PD ‐ L1 inhibitors combined with chemotherapy in advanced gastroesophageal carcinomas: A systematic review and meta‐analysis
Open Access
- 6 January 2026
- journal article
- review article
- Published by Wiley in Precision Medical Sciences
- Vol. 15 (1) , 42-56
Abstract
Advanced gastroesophageal cancers often have poor survival rates even with chemotherapy. We aim to study the long‐term safety and efficacy of combining PD‐1/PD‐L1 inhibitors with chemotherapy, incorporating biomarker analysis and recent Phase III trial data. Data from eight phase III trials (from inception to 2025, comprising 5668 patients) was combined in this PRISMA‐guided meta‐analysis. Overall survival (OS), objective response rate (ORR), progression‐free survival (PFS), and grade ≥3 adverse events were among the outcomes. Random‐effects models were employed for statistical synthesis, and I 2 was used to assess the heterogeneity. Cochrane RoB 2.0 was used to evaluate the risk of bias. Compared to chemotherapy alone, the combined regimen significantly improved overall survival (HR: 0.79; 95% CI: 0.75–0.83; p < .0001), progression‐free survival (HR: 0.73; 95% CI: 0.68–0.78; p < .00001), and objective response rate (OR: 1.60; 95% CI: 1.44–1.78; p < .0001). The CPS ≥10 subgroups showed the greatest benefits (OS HR, 0.66; PFS HR, 0.63; p < .0001). Although manageable, grade ≥3 adverse events (OR, 1.37; 95% CI: 1.20–1.56) and immune‐related toxicities (OR: 3.44; 95% CI: 2.91–4.08) were more common with ICIs. The OS advantage was greatest for MSI‐high tumors (HR: 0.54; p < .04), but was not significant for esophageal cancers (HR: 0.88; p < .18). With long‐lasting improvements in survival and manageable toxicity, PD‐1/PD‐L1 inhibitors in combination with chemotherapy constitute the first‐line standard for advanced gastric/GEJ malignancies. Immune checkpoint inhibitors show a higher incidence of adverse events, and clinicians should balance efficacy against adverse event risk.Keywords
This publication has 30 references indexed in Scilit:
- PD-1/PD-L1 Inhibitors in Combination With Chemo or as Monotherapy vs. Chemotherapy Alone in Advanced, Unresectable HER2-Negative Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: A Meta-AnalysisClinical Oncology, 2024
- The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2023Cancer Communications, 2023
- Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction CancerJAMA, 2023
- Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trialThe Lancet Oncology, 2022
- First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trialThe Lancet, 2021
- Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trialThe Lancet Oncology, 2019
- Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trialThe Lancet, 2018
- Oesophageal cancerThe Lancet, 2017
- Effect of Fluorouracil, Leucovorin, and Oxaliplatin With or Without Onartuzumab in HER2-Negative, MET-Positive Gastroesophageal AdenocarcinomaJAMA Oncology, 2017
- Induction of Immunogenic Cell Death by Chemotherapeutic Platinum ComplexesAngewandte Chemie International Edition, 2015